Pub. Date : 2016 May
PMID : 26941173
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A Food and Drug Administration-approved antiviral agent, known as vidarabine or adenine 9-beta-D-arabinofuranoside (AraA), has features of inhibiting adenylyl cyclase type 5 (AC5) and protects against chronic coronary artery occlusion (CAO). | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 2 | A Food and Drug Administration-approved antiviral agent, known as vidarabine or adenine 9-beta-D-arabinofuranoside (AraA), has features of inhibiting adenylyl cyclase type 5 (AC5) and protects against chronic coronary artery occlusion (CAO). | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 3 | A Food and Drug Administration-approved antiviral agent, known as vidarabine or adenine 9-beta-D-arabinofuranoside (AraA), has features of inhibiting adenylyl cyclase type 5 (AC5) and protects against chronic coronary artery occlusion (CAO). | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 4 | The reduction in infarct size with AraA was prevented by a MEK/extracellular signal-regulated kinase blocker, a pathway also involved in the mechanism of protection of the AC5 knockout (KO) model. | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 5 | Infarct size was also reduced in cardiac-specific AC5 KO mice similarly in the presence and absence of AraA, further suggesting that AraA protection involves the AC5 pathway. | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 6 | Infarct size was also reduced in cardiac-specific AC5 KO mice similarly in the presence and absence of AraA, further suggesting that AraA protection involves the AC5 pathway. | Vidarabine | adenylate cyclase 5 | Mus musculus |
| 7 | Infarct size was also reduced in cardiac-specific AC5 KO mice similarly in the presence and absence of AraA, further suggesting that AraA protection involves the AC5 pathway. | Vidarabine | adenylate cyclase 5 | Mus musculus |